Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Nonrandomized, Single-Dose, Safety and Pharmacokinetic Study of LY3537982 in Participants With Hepatic Impairment and Healthy Participants

NCT06719128 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06719128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06719128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Nonrandomized, Single-Dose, Safety and Pharmacokinetic Study of LY3537982 in Participants With Hepatic Impairment and Healthy Participants
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
December 6, 2024
Completion date
August 25, 2025
Enrollment
46 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, hepatic insufficiency